Use of the IGF-I antisense strategy in the treatment of the hepatocarcinoma

Adv Exp Med Biol. 1998:451:35-42. doi: 10.1007/978-1-4615-5357-1_6.

Authors

L C Upegui-Gonzalez¹, H T Duc, Y Buisson, M Arborio, C Lafarge-Frayssinet, C Jasmin, Y Guo, J Trojan

Affiliation

¹ Hôpital Paul Brousse, Université Paris XI, Villejuif, France.

PMID: 10026847
DOI: 10.1007/978-1-4615-5357-1_6

No abstract available

MeSH terms

Animals
Antigens, Viral, Tumor / genetics
Antithrombin III / genetics
Antithrombin III / physiology
Apoptosis
Carcinoma, Hepatocellular / genetics
Carcinoma, Hepatocellular / pathology
Carcinoma, Hepatocellular / therapy*
DNA, Antisense*
Genetic Therapy*
Humans
In Situ Nick-End Labeling
Insulin-Like Growth Factor I / genetics*
Liver Neoplasms / genetics
Liver Neoplasms / pathology
Liver Neoplasms / therapy*
Liver Neoplasms, Experimental / genetics
Liver Neoplasms, Experimental / therapy*
Major Histocompatibility Complex
Mice
Mice, Transgenic
Promoter Regions, Genetic
Simian virus 40 / genetics
Tumor Cells, Cultured

Substances

Antigens, Viral, Tumor
DNA, Antisense
Insulin-Like Growth Factor I
Antithrombin III